Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma.
Yuto YamadaYuta OhnoYu KatoRyo KobayashiHideki HayashiShiho MiyaharaKeita NakaneKosuke MizutaniShigeaki YokoiHironori FujiiHirotoshi IiharaTakuma IshiharaTakashi DeguchiTadashi SugiyamaAkio SuzukiPublished in: Cancer chemotherapy and pharmacology (2019)
Our findings suggest that the optimal dose of sunitinib for Asian, including Japanese, patients with mRCC is ≤ 37.5 mg/day.